Komo

Biopharmaceutical company

What is Celltrion?

Celltrion is a biopharmaceutical company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.

Category
Biopharmaceutical company
Headquarters
Incheon, South Korea
Founded
See official company history
Employees
See latest annual report and company filings
Total funding
Public company
Status
Public company; KRX: 068270

What is Celltrion?

Celltrion is a biopharmaceutical company company headquartered in Incheon, South Korea. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.

Celltrion is a biopharmaceutical company company headquartered in Incheon, South Korea. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.

For sellers, Celltrion should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.

What does Celltrion offer?

Celltrion's profile centers on Biosimilars, Biologics, Antibody medicines, Manufacturing.

  • Biosimilars· Biopharmaceutical company
  • Biologics· Biopharmaceutical company
  • Antibody medicines· Biopharmaceutical company
  • Manufacturing· Biopharmaceutical company
  • Clinical development· Biopharmaceutical company
  • Global commercialization· Biopharmaceutical company

How does Celltrion make money?

Celltrion makes money through commercial activity tied to biopharmaceutical company.

Celltrion monetizes through the model common to biopharmaceutical company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.

Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.

Who leads Celltrion?

Celltrion's named executives should be verified on the official leadership or investor-relations page before outreach.

  • Celltrion executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
  • Celltrion finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
  • Celltrion operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.

How do you contact Celltrion's leadership?

Celltrion should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.

Email formatcontact via https://www.celltrion.com

How is Celltrion funded?

Celltrion's current status is Public company; KRX: 068270.

Celltrion's capital profile is best understood through its current public-company status: Public company; KRX: 068270. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.

Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.

How did Celltrion get here?

Celltrion's history should be read through founding, scale-up, public-market ownership, and current product or market focus.

  1. FoundingCelltrion is foundedThe company begins building in biopharmaceutical company.
  2. Scale-upCommercial footprint expandsCelltrion broadens its product, customer, distribution, or geographic reach.
  3. Public marketsPublic company; KRX: 068270Public-company ownership shapes reporting, procurement, and operating priorities.
  4. 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
  5. June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.

Who are Celltrion's competitors?

Celltrion competes with larger incumbents and focused specialists in biopharmaceutical company.

  • PfizerGlobal pharmaceutical company.
  • RochePharmaceuticals and diagnostics company.
  • NovartisGlobal medicines company.
  • Samsung BiologicsBiologics CDMO.
  • CSLBiotechnology company.

Celltrion — frequently asked questions

Agent CTA Background

Revenue work. On autopilot.

Start Free TrialBuilt for revenue teams who care about quality.